Physician profile
Robert D Lieberman
NPI 1639308943
$21,688.24
in general payments reported to CMS, 2019-2025
31 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,510 · 2021: $810 · 2022: $1,766 · 2023: $1,459 · 2024: $1,513 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,384 · Education: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,384.41 |
| Education | $415.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,982.64 | 2019-2025 | |
| Biofrontera INC. | $5,753.58 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Abbvie INC. | $1,870.89 | 2019-2025 | |
| Janssen Biotech, INC. | $1,144.62 | 2019-2025 | Tremfya |
| Merz North America, INC. | $956.82 | 2019-2022 | |
| Genzyme Corporation | $697.33 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $667.12 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $653.32 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Leo Pharma INC. | $426.03 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $351.14 | 2019-2025 | Nemluvio |
| Ucb, INC. | $303.90 | 2020-2025 | Bimzelx |
| Amgen INC. | $273.06 | 2019-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.70 | 2022-2024 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $209.55 | 2019-2025 | Libtayo, Dupixent |
| Sanofi-Aventis U.S. LLC | $200.20 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $197.18 | 2023-2024 | Zoryve |
| Genentech USA, INC. | $186.16 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $118.74 | 2019 | |
| Incyte Corporation | $99.12 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $54.45 | 2022-2023 | Valchlor |
| Almirall LLC | $49.93 | 2019-2020 | |
| Dermavant Sciences, INC. | $47.35 | 2023-2024 | Vtama |
| Botanix Sb INC | $42.99 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $37.39 | 2025 | Sotyktu |
| Celgene Corporation | $35.45 | 2019 | |
| Dermira, INC. | $32.67 | 2019 | |
| Lilly USA, LLC | $25.99 | 2025 | Ebglyss |
| Organon LLC | $21.73 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $17.58 | 2019 | |
| Epi Health, LLC | $9.61 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.